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Abstract
Viable cancer cells can commonly be recovered from surgical sites and venous blood during tumor resection. The
adhesion of these cells to surrounding tissues may impact patient outcomes. Iatrogenic exposure to increased
extracellular pressure modulates integrin binding affinity and stimulates colon cancer cell adhesion in vitro through
an α-actinin-1–dependent signaling pathway. We hypothesized that preoperative small interfering RNA–mediated
silencing of α-actinin-1 in tumor tissue could disrupt pressure-stimulated cancer cell adhesion to murine surgical
wounds and thereby enhance subsequent tumor-free survival. Reducing α-actinin-1 in CT26 murine adenocar-
cinoma cells blocked cell adhesion to collagen in vitro and similarly inhibited pressure-induced CT26 implantation
in murine surgical wounds in vivo. Surgical wound contamination with pressure-activated CT26 cells significantly
reduced tumor-free survival compared to contamination with tumor cells maintained under ambient pressure.
However, mice treated with pressure-activated CT26 cells preoperatively transfected with α-actinin-1–specific
small interfering RNA displayed reduced surgical site implantation and increased tumor-free survival compared
to mice exposed to pressure-activated cells expressing normal levels of α-actinin-1 protein. These results suggest
that pressure activation of malignant cells promotes tumor development and impairs tumor-free survival. α-Actinin-1
may be an effective therapeutic target to inhibit perioperative pressure-stimulated tumor cell implantation.
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Introduction
Iatrogenic tumor cell implantation within surgical wounds can com-
promise curative cancer surgery. Surgical dissemination of viable tumor
cells within the peritoneal cavity, wound site, portal, and systemic ve-
nous circulation occurs in as many as 50% of patients during colon
cancer resection [1–3]. Whereas the presence of free malignant cells
represents a poor prognostic factor [4,5], the frequency at which these
shed tumor cells result in perioperative metastases is difficult to quan-
tify [6,7]. However, wound recurrence and distant metastasis due to
perioperative tumor dissemination does occur [8,9]. Reducing the im-
plantation of shed tumor cells may therefore be beneficial.
We have previously reported that exposure to physical forces includ-
ing increased extracellular pressure, laminar, and nonlaminar shear stim-
ulates colon cancer cell adhesion to matrix proteins, endothelial cell
monolayers, and surgical wounds in vivo by modulating integrin bind-
ing affinity through a cytoskeleton- and focal adhesion complex–
dependent signaling mechanism [10–14]. Shed tumor cells may be sub-
jected to these mechanical stimuli during vascular and lymphatic tran-
sits, in the tumor microenvironment, or iatrogenically through surgical
manipulation, laparoscopic insufflation, and postoperative bowel edema
[15–19]. Cells from colon, breast, and glossal cancer lines, murine co-
lonic adenocarcinomas, and primary human colon cancers all display
similar pressure-mediated phenomena [10–12,20,21].
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α-Actinin-1 is a crucial upstream component of the mechanical
response pathway mediating pressure-stimulated cell adhesion [22].
α-Actinin is a ubiquitously expressed actin–cross-linking protein lo-
calized primarily along cytoskeletal filaments and at focal adhesion
plaques in nonmuscle cells [23,24]. Increased pressure induces redistri-
bution of α-actinin-1 to the membrane where it functions as an adapter
protein and facilitates Src recruitment to β1-integrin–associated focal ad-
hesions [22]. In this same study, a modest reduction in α-actinin-1 ex-
pression was able to completely disrupt pressure-mediated effects on
tumor cell adhesion to type I collagen in vitro without significantly
altering basal adhesion under ambient pressure conditions. These re-
sults suggested that α-actinin-1 expression is rate limiting under elevated
pressures. The sensitivity of pressure-induced phenomena to α-actinin-1
manipulation suggests that α-actinin-1 may have potential as a therapeu-
tic target for the inhibition of pressure-stimulated tumor cell adhesion.
We therefore postulated that preoperative reduction of α-actinin-1
expression in tumor tissue would block pressure-induced alterations in
tumor cell adhesiveness and minimize wound implantation and tumor
recurrence in an animal model. To test this hypothesis, we used small
interfering RNA (siRNA) to selectively reduceα-actinin-1 protein inmu-
rine CT26 colon carcinoma cells. We assessed the effect of α-actinin-1
reduction on pressure-stimulated CT26 cell adhesion to collagen I
in vitro and implantation in murine surgical wounds in vivo. Further-
more, using a previously characterized murine survival model [11], we
assessed the impact of pressure activation of CT26 cells and α-actinin-1
reduction on tumor-free survival.
Materials and Methods
Cell Culture
CT26 is an N-nitroso-N-methylurethane–induced BALB/c undiffer-
entiated colon carcinoma (American Type Culture Collection, Manas-
sas, VA). CT26 cells were maintained as previously described [25].
Pressure Regulation
Pressure was controlled using an airtight Lucite box with an inlet
valve for gas application and an outlet valve connected to a manome-
ter [10]. The box was prewarmed to 37°C to prevent internal tem-
perature and pressure fluctuations. Temperature was maintained
within ±2°C and pressure within ±1.5 mm Hg of desired levels.
Cell Adhesion Assay
Suspended cells were allowed to adhere to collagen I–coated six-well
plates (105 cells/well) for 30 minutes at 37°C under ambient and in-
creased pressure (+15 mm Hg) conditions. After 30 minutes, non-
adherent cells were gently washed away with warm phosphate-buffered
saline (PBS), and adherent cells were formalin-fixed, hematoxylin-
stained, and each well was counted in 20 or more random high-power
fields using an inverted microscope [10].
Wound Implantation Studies
Bilateral 1-cm groin incisions were made in BALB/c mice anesthe-
tized with 60 mg/kg intraperitoneal pentobarbital. Equal 100-μl sus-
pensions of 105 51Cr-labeled CT26 cells were applied to each wound,
with each mouse serving as its own control. Suspensions were aspirated
after 30 minutes, and the wounds were vigorously washed with PBS.
The mice were then euthanized, and the wounds were excised postmor-
tem for the quantification of tumor adhesion. Radioactivity in the ex-
cised tissue was measured using an automated scintillation counter as
previously detailed [26]. In parallel survival studies, equal suspensions
of 104 unlabeled cells were placed on single-flank incisions. Suspensions
were aspirated after 30 minutes, and the wounds were vigorously
washed and closed. The mice were followed for 90 days to assess tumor
development and were sacrificed once tumors achieved 100-mg size.
Tumors were measured five times per week and mass were estimated
from two-dimensional measurements. The tumor weight was calculated
in mg = (a × b2)/2, where a and b are the tumor length and width in
mm, respectively [27].
Transfection
Cells were transfected with 50 nM double-stranded siRNA directed
toward the mRNA target 5′-CACAGAUCGAGAACAUCGAAG-3′
for α-actinin-1 (Dharmacon, Lafayette, CO) as previously described
[22]. A Dharmacon siCONTROL Non-Targeting siRNA #1 sequence
was used as a control. Cell transfectants were used for adhesion experi-
ments after 48 hours.
Western Blot Analysis
Cell lysates were prepared as previously described [28]. Equal
amounts of protein were resolved by SDS-PAGE and transferred to
Hybond ECL nitrocellulose membrane (Amersham Pharmacia Bio-
tech, Piscataway, NJ). Mouse monoclonal antibodies to α-actinin-1
(US Biological, Swampscott, MA) and glyceraldehyde-3-phosphate
dehydrogenase (Biodesign International, Saco, MN) coupled with
anti–mouse horseradish peroxidase–conjugated secondary antibodies
(Cell Signaling, Beverly, MA) were used for the immunodetection of
blotted proteins. Bands were detected with enhanced chemilumines-
cence (Amersham Pharmacia Biotech) and analyzed with a Kodak
Image Station 440CF (Perkin Elmer, Boston, MA).
Cell Proliferation Assay
Cell proliferation was assessed by colorimetric analysis of 3-(4,5-
dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide (MTT; ATCC)
reduction every 24 hours. Absorbance values were obtained at a wave-
length of 570 nm using a spectrophotometer.
Results and Discussion
Previous studies demonstrated that a 30-minute exposure to 15 mm
Hg–increased extracellular pressure stimulates human colon cancer
cell adhesion to collagen I by approximately 20% to 50% compared
to cells under ambient conditions [10,12,26]. We initially sought to
determine whether murine CT26 colon carcinoma cells respond sim-
ilarly to increased pressure and whether siRNA-mediated reduction
of α-actinin-1 blocks this effect. We used a previously characterized
α-actinin-1–specific siRNA sequence (siACTN1) selected because
of the perfect human–murine homology of the targeted region of
mRNA [22]. Similar to previous observations, siRNA transfection of
CT26 cells reduced total α-actinin-1 protein by 74 ± 6% (Figure 1A;
n = 11; P < .01). Suspended CT26 cells were exposed to either ele-
vated or ambient pressure conditions and evaluated for in vitro adhe-
sion to collagen I (Figure 1B). Control nontargeting siRNA (siNT)–
transfected CT26 cells displayed a 54 ± 9% (n = 6; P < .04) increase in
adhesion after a 30-minute exposure to 15 mm Hg–elevated pressure.
α-Actinin-1 silencing moderately reduced basal CT26 cell adhesion by
26 ± 5% (n = 6; P < .04) and completely blocked the increase in ad-
hesion that accompanies exposure to elevated pressure.
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Preliminary in vivo studies demonstrated that preexposure to in-
creased pressure enhances murine tumor cell implantation to surgical
wounds [26]. Therefore, we next confirmed that α-actinin-1 reduction
also inhibits pressure-induced CT26 cell adhesion to murine tissues
in vivo. Suspended CT26 cell transfectants were labeled with radioac-
tive 51Cr and exposed to either ambient or increased pressure condi-
tions. Equal aliquots of control and pressure-treated cell suspensions
were placed in bilateral groin incisions, using each mouse as its own
control, for 30 minutes before the wounds were vigorously washed with
PBS to remove nonadherent cells, and the surgical wounds were excised
postmortem. Relative radioactivity of the excised wounds was used to
quantify CT26 cell implantation (Figure 2). Preexposure to 15 mm
Hg–elevated pressure increased siNT-transfected CT26 cell adhesion
to murine wounds by 66 ± 14% (n = 5; P < .01) compared to those
under ambient conditions. In contrast, siACTN1 transfection moder-
ately reduced basal counts by 31 ± 9% (n = 5; differences not signifi-
cant) and prevented the stimulation of adhesion by pressure.
We next sought to determine whether the observed pressure-
mediated increases in the number of cells adhering to surgical wounds
have consequences for murine tumor development and tumor-free
survival. As in the wound implantation studies, CT26 cells were trans-
fected with either NT or ACTN1 siRNA in vitro, and after 48 hours,
cell suspensions were exposed to ambient or increased pressure condi-
tions. Equal aliquots of the cell suspensions were placed on single sur-
gical incisions in the anesthetized mice. After 30 minutes, the wounds
were washed and closed. Mice were examined daily for the develop-
ment of a palpable tumor and growth was charted until a total tumor
burden of 100 mg was reached to provide objective evidence of differ-
ences in rates of tumor development to correlate with the subjective
impression of a palpable tumor (Figure 3). The 100-mg tumor burden
was predetermined as a final endpoint in consultation with our veter-
inarians based on animal welfare considerations. Of the mice treated
with siNT control cells, 56% developed tumors. On average, palpable
tumors were observed by 21 days in the control group and a 100-mg
tumor burden was reached by day 28. Of the mice exposed to pressure-
activated CT26 cells, 76% developed tumors. The average tumor-free
survival in the siNT pressure group was reduced to 15 days, and
maximal tumor burden was reached by 21 days. The log-rank statistic
for the plot of time to palpable tumor (Figure 3A) suggests that the
difference in curves between siNT control and pressure groups is sta-
tistically significant (n = 25; P = .04). The curves depicting average
time until a 100-mg tumor burden (Figure 3B) correlated with the time
Figure 2. Effect of α-actinin-1 reduction on pressure-mediated
CT26 tumor cell wound implantation. The 15 mm Hg–increased
pressure (closed bars) stimulates the adhesion of siNT-transfected,
51Cr-labeled CT26 cells to murine surgical wounds compared with
cells kept under ambient pressure conditions (open bars). Pressure
failed to increase wound implantation of CT26 cells transfected
with siACTN1 (*P < .01; n = 5). Adhesion was determined by the
acquired radioactive counts per minute (cpm) of surgical wounds
after a 30-minute exposure to 51Cr-labeled CT26 cells. Data were
analyzed by paired Student’s t test and graphically expressed as
mean ± SEM.
Figure 1. Effect of siRNA-mediated reduction of α-actinin-1 on pressure-stimulated murine colon cancer cell adhesion to collagen I. (A)
Typical reduction of α-actinin-1 protein in CT26 cells transfected with siRNA targeted to α-actinin-1 (siACTN1) compared with cells trans-
fected with a nontargeting sequence (siNT) as measured by Western blot analysis. Glyceraldehyde-3-phosphate dehydrogenase was
used as a loading control, and α-actinin-1 protein expression is normalized against that of siNT-transfected cells (*P < .01; n = 11). (B)
The 15 mm Hg–increased extracellular pressure (closed bars) stimulates siNT-transfected CT26 cell adhesion to collagen I compared
with ambient pressure controls (open bars). CT26 cells transfected with siACTN1 fail to display any increase in adhesion due to pressure
(*P < .04; n = 6; #P < .04 comparison of siNT versus siACTN1 adhesion under ambient pressure). Data from individual experiments
were normalized to the siNT ambient pressure controls and graphically expressed as mean ± SEM. Statistical analysis was by Wilcoxon
matched-pairs signed-ranks test.
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to palpable tumor curves and were similarly deemed to be significantly
different between control and pressure groups (n = 25; P < .03).
The effect of siRNA-mediated α-actinin-1 reduction on murine
tumor-free survival was examined in parallel (Figure 3). Of the mice
exposed to siACTN1-treated control cells, 52% developed tumors.
Palpable tumors were observed, on average, at 28 days and a 100-mg
tumor burden was reached by day 42. No significant difference was
found between siNT- and siACTN1-treated survival and time to
palpable tumor curves under ambient pressure. Consistent with our
previous data, only 56% of the mice exposed to pressure-activated,
siACTN1-transfected CT26 cells developed tumors. The average
tumor-free survival was 24 days and max tumor burden was reached
by 37 days. Differences between siACTN1-transfected cells exposed
to either ambient or increased pressure conditions were not significant.
However, log-rank analysis of the difference between the curves for
siNT- and siACTN1-treated, pressure-activated cells for both time to
palpable tumor and 100-mg tumor burden are each statistically signif-
icant (n = 25; P < .05 for each). These results suggest that preoperative
reduction of α-actinin-1 expression ablates the deleterious effects of
pressure on wound implantation and enhances tumor-free survival.
Finally, we sought to address whether the altered rates of tumor
development observed between experimental groups reflect only differ-
ences in cell adhesiveness during the surgical procedure or are addi-
tionally influenced by differences in CT26 cell proliferation from
exposure to increased pressure or loss of α-actinin-1. Forty-eight hours
after initial transfection, suspended siNT and siACTN1 transfectants
were exposed to either ambient or increased pressure conditions for
30 minutes, mimicking the treatment of cells before their use in sur-
vival studies. CT26 cells were then lightly seeded and assessed for rates
of proliferation determined by the colorimetric reduction of MTT
in 24-hour increments (Figure 4). No significant differences were
Figure 3. Effect of preoperative siRNA-mediated α-actinin-1 silenc-
ing on murine tumor development and survival after exposure to in-
creased pressure. Exposure of CT26 cells to elevated pressure
increases the rate of surgical wound implantation, whereas preoper-
ative silencing of α-actinin-1 inhibits the pressure-mediated effect.
(A) The Kaplan-Meier graph depicts the incidence of palpable tumor
development over time. The solid black line plots the time to palpa-
ble tumor in mice exposed to siNT-transfected CT26 cells kept under
ambient pressure. The interrupted black line represents exposure
to pressure-activated siNT-transfected cells. The respective gray
curves depict mice treated with parallel populations of CT26 cells
transfected with siACTN1 (*P < .05; n = 25). (B) The Kaplan-Meier
graph depicts the incidence of tumors reaching 100 mg over time.
Pressure activation increases the rate at which the mice reach a crit-
ical tumor burden. siRNA-Mediated reduction of α-actinin-1 blocks
this effect (*P < .05; n = 25). Survival data were analyzed by log-
rank statistic.
Figure 4. Effect of increased pressure and α-actinin-1 reduction on
CT26 cell proliferation. CT26 cells were transfected with either
siACTN1 or siNT and, after 48 hours, were exposed to either
15 mm Hg–increased pressure or ambient pressure conditions.
After exposure to pressure (time 0), cell proliferation of the respec-
tive populations was assessed by colorimetric analysis of MTT re-
duction every 24 hours. No significant difference in the rate of
proliferation was observed between experimental groups (n =
4). All data are represented as mean ± SEM.
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observed between any of the experimental groups (n = 4). This is con-
sistent with our previous observation that increased pressure stimulates
SW620 colon cancer cell proliferation only when sustained for at least
412 hours [29].
These results demonstrate that pressure activation of malignant cells
has a biologic consequence for subsequent tumor development and
tumor-free survival in an animal model. In addition, this study raises
the possibility that perioperative therapeutic interventions can prevent
this effect and reduce tumor recurrence. α-Actinin-1’s lack of kinase
activity makes it impervious to conventional pharmacologic pertur-
bation and, therefore, an ideal target for RNA interference–based in-
hibitory strategies. While the therapeutic use of siRNA to silence
disease-causing genes in humans is still in its infancy, preliminary re-
ports from clinical trials are encouraging [30,31]. Although siRNA-
mediated reduction of α-actinin-1 in this study was conducted in vitro
and clinical translation would require consideration of preoperative
access to the primary tumor, the reduction in basal adhesion and com-
plete blockade of pressure-stimulated tumor cell adhesion accom-
plished through its silencing is proof-of-principle that α-actinin–like
molecules may be suitable perioperative targets to reduce the metastasis
of surgically disseminated cells.
Detection of free tumor cells in venous blood and peritoneal la-
vage from patients undergoing surgery for colorectal cancer is a sig-
nificant predictor of tumor recurrence [5]. Factors influencing the
subsequent implantation of shed tumor cells are of obvious clinical
interest. Taken together with previous in vitro observations, our cur-
rent results further suggest that perioperative exposure of malignant
colonocytes to increased pressure and shear engendered by surgical
manipulation, laparoscopic peritoneal insufflation, and intraabdomi-
nal third spacing may activate cancer cell adhesion and potentiate
tumor metastasis.
Despite the relative rarity of wound recurrence, many other measures
have been described in human surgery to avoid wound recurrence
of resected tumors, including specialized techniques, mechanical irri-
gation, port site and intraabdominal chemotherapy, and even the
secondary excision of the surgical wounds themselves [3,32–34]. Un-
fortunately, little data support the efficacy of such interventions. Al-
though localized wound irrigation with calcium chloride can also
reduce tumor cell implantation in mice [11], this strategy falls short
in its ability to block pressure-induced integrin affinity modulation
and has no effect on the adhesion of tumor cells shed into the vas-
cular and lymphatic circulation. A means of systemically targeting the
pressure-induced adhesion pathway preoperatively would likely be
the most efficacious. Whether preoperative intratumoral or intrave-
nous administration of α-actinin-1 siRNA could be a suitable thera-
peutic option requires further study.
There are obviously manifest differences between the surgical resec-
tion of CT26 colon carcinomas in mice and human colon cancers.
The actual baseline incidence of clinically significant tumor recurrence
in surgical wounds is much lower than the rates observed in this study.
Here, we specifically titered the number of tumor cells seeded into
each surgical wound to dramatically increase the number of tumor re-
currences over that which is observed after human colectomy for can-
cer to increase the power of our study with a realistic sample size.
Therefore, this model clearly demonstrates the long-term negative im-
pact of increased pressure on colon cancer cell adhesion and supports
the notion that effectively targeting this pathway can limit the implan-
tation of shed tumor cells and enhance tumor-free survival.
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